etrasimod

Ventyx reports positive phase 2 data for bowel disease drug, but fails to impress investors amid competition

Investors have shown skepticism toward Ventyx Biosciences’ attempt to challenge Bristol Myers Squibb and Pfizer in the ulcerative colitis market. ...